1000 subjects with chronic, moderate heart failure (NYHA functional class II-III) with reduced ejection fraction (≤45%) will be enrolled (500 randomly allocated to receive and 500 to receive placebo in addition to standard therapy). Determination of study eligibility will be established by the Investigator on the basis of the inclusion and exclusion criteria.